NCT00060125View on ClinicalTrials.gov

Tipifarnib in Treating Patients With Metastatic Malignant Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

June 30, 2006

Conditions
Recurrent MelanomaStage IV Melanoma
Interventions
DRUG

tipifarnib

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60606

Cancer and Leukemia Group B, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00060125 - Tipifarnib in Treating Patients With Metastatic Malignant Melanoma | Biotech Hunter | Biotech Hunter